

I. AMENDMENTS

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (currently amended) A method of treatment for a mammal, with advanced or large tumor burdens, comprising administering from 60-180 µg of deoxyribonucleic acid (DNA) encoding B7.1 the administration to said mammal of a T-cell co-stimulatory-cell-adhesion molecule (CAM) prior to administering in conjunction with a tumor growth-restricting agent, either of which alone would be ineffective in treating an advanced or large tumor burden, wherein said CAM is B7.1 and wherein said tumor growth restricting agent is an optimal dose of DMXAA, thereby treating said mammal.

2. (currently amended) A method of treating a patient with cancer ~~which comprises the step of administering to said patient a CAM and a tumor growth-restricting agent in amounts which are together effective to treat any advanced or large tumors present, wherein said CAM is comprising administering from 60-180 µg of DNA encoding B7.1 prior to administering and wherein said tumor growth-restricting agent is~~ an optimal dose of DMXAA, thereby treating said patient.

3. (currently amended) A method of potentiating the activity of a CAM against tumors present in a patient suffering from cancer ~~which comprises the step of administering to said patient treated with said CAM an amount of a tumor growth-restricting agent, which is effective, in combination with said CAM to treat any advanced or large tumors present in said patient, wherein said CAM is B7.1 when administered to a patient suffering from cancer and by administering an optimal dose of wherein said tumor growth-restricting agent is DMXAA subsequent to~~ DNA encoding said B7.1, thereby potentiating said activity.

4. (currently amended) A method of as claimed in claim 3, wherein potentiating the activity of a tumor growth-restricting agent against tumors present in a patient suffering from

~~cancer which comprises the step of pre-administering to a patient to be treated with said tumor growth-restricting agent an amount of CAM which, upon subsequent administration of said tumor growth-restricting agent, acts in combination with said tumor growth-restricting agent to treat an advanced or large tumors present, wherein said CAM is a dose of said B7.1 comprises from 60-180 μ g of said DNA encoding B7.1 and wherein said tumor growth-restricting agent is DMXAA.~~

5-9. (canceled).

10. (withdrawn) A method as claimed in claim 1, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).

11. (withdrawn) A method as claimed in claim 10, wherein the wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

12. (canceled).

13. (currently amended) A method as claimed in claim ~~[[12]]~~ 1, wherein ~~the CAM~~ said DNA encoding B7.1 is administered from 12 to 48 hours prior to the administration of said DMXAA ~~the tumor growth-restricting agent.~~

14. (currently amended) A method as claimed in claim 1, wherein the method further ~~includes~~ comprises the administration of an additional tumor growth-restricting agent.

15. (withdrawn) A method as claimed in claim 14, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF-1).

16-17. (canceled).

18. (withdrawn) A method as claimed in claim 2, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).

19. (withdrawn) A method as claimed in claim 18, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

20. (canceled).

21. (currently amended) A method as claimed in claim [[20]] 2, wherein said DNA encoding B7.1 the CAM is administered from 12 to 48 hours prior to the administration of said DMXAA the tumor growth-restricting agent.

22. (currently amended) A method as claimed in claim 2, wherein the method further includes comprises the administration of an additional tumor growth-restricting agent.

23. (withdrawn) A method as claimed in claim 22, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF- 1).

24-25. (canceled).

26. (withdrawn) A method as claimed in claim 3, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).

27. (withdrawn) A method as claimed in claim 26, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

28. (canceled).

29. (currently amended) A method as claimed in claim [[28]] 3, wherein the said DNA encoding B7.1 CAM is administered from 12 to 48 hours prior to the administration of said DMXAA tumor growth-restricting agent.

30. (currently amended) A method as claimed in claim 3, wherein the method further includes comprises the administration of an additional tumor growth-restricting agent.

31. (withdrawn) A method as claimed in claim 30, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF-1).

32-33. (canceled).

34. (withdrawn) A method as claimed in claim 4, wherein the tumor growth-restricting agent is an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).

35. (withdrawn) A method as claimed in claim 34, wherein the tumor growth-restricting agent is an expression vector which encodes an anti-sense version of HIF-1.

36. (canceled).

37. (currently amended) A method as claimed in claim ~~[[36]]~~ 4, wherein said DNA encoding B7.1 ~~the CAM~~ is administered from 12 to 48 hours prior to the administration of said DMXAA ~~the tumor growth-restricting agent~~.

38. (currently amended) A method as claimed in claim 4, wherein the method further ~~includes~~ comprises the administration of an additional tumor growth-restricting agent.

39. (withdrawn) A method as claimed in claim 38, wherein the additional tumor growth restricting agent comprises an expression vector encoding an anti-sense version of hypoxia-inducible factor-1 (HIF- 1).

40-55. (canceled).

56. (New) A method as claimed in any of claims 1-3, wherein said DNA encoding B7.1 is administered in an expression vector.

57. (New) A method as claimed in claim 56, wherein said expression vector is a plasmid, an adenoviral-based vector or a retroviral-based vector.

58. (New) A method as claimed in any of claims 1-3, wherein said DNA is administered by injected into one or more sites in the tumor.

[REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK]